Volume 39 Issue 5
May  2023
Turn off MathJax
Article Contents
Article Navigation >  Journal of Nanjing University of traditional Chinese Medicine  > 2023  >  39(5): 420-432
JIN Tian-zi, LUO Zi-chen, XU Wei-chen, CHONG Ying, SHI Chen, SHAN Jin-jun. Using Lipidomics Technology to Investigate the Regulatory Impact of Jianpi Lishi Formula on Lipid Metabolism in NAFLD Mice[J]. Journal of Nanjing University of traditional Chinese Medicine, 2023, 39(5): 420-432. doi: 10.14148/j.issn.1672-0482.2023.0420
Citation: JIN Tian-zi, LUO Zi-chen, XU Wei-chen, CHONG Ying, SHI Chen, SHAN Jin-jun. Using Lipidomics Technology to Investigate the Regulatory Impact of Jianpi Lishi Formula on Lipid Metabolism in NAFLD Mice[J]. Journal of Nanjing University of traditional Chinese Medicine, 2023, 39(5): 420-432. doi: 10.14148/j.issn.1672-0482.2023.0420
shu

Using Lipidomics Technology to Investigate the Regulatory Impact of Jianpi Lishi Formula on Lipid Metabolism in NAFLD Mice

doi: 10.14148/j.issn.1672-0482.2023.0420
  • 1.

    Institute of Pediatrics, Nanjing University of Chinese Medicine, Nanjing 210023, China

  • 2.

    Medical Metabolomics Center, Nanjing University of Chinese Medicine, Nanjing 210023, China

  • 3.

    Jiangsu Engineering Research Center for Efficient Delivery System of Traditional Chinese Medicine, Nanjing University of Chinese Medicine, Nanjing 210023, China

  • Received Date: 2022-12-01
    Available Online: 2023-05-19
    Abstract
  •   OBJECTIVE  To explore the regulatory effect of Jianpi Lishi Formula on liver lipid metabolism in NAFLD mice based on LC-MS lipidomics.  METHODS  C57BL/6J mice were randomly divided into three groups: blank group, model group, and Jianpi Lishi Formula group, with 6 mice in each group. NAFLD models were induced by feeding them 60% high-fat feed for 12 weeks, during which medication intervention was also performed. The pharmacodynamic evaluation was conducted through biochemical indicator detection and pathological sections, while LC-MS lipidomics was used to detect lipid changes in mouse liver tissue.  RESULTS  Jianpi Lishi Formula improved the increase in body mass induced by HFD. HE and oil red staining showed that it had a liver protective effect and could restore glucose metabolism levels. Also, Jianpi Lishi Formula decreased the mRNA levels of Fasn, CD36, SCD1, and Srebp1c in the liver (P < 0.05, P < 0. 01, P < 0. 001). Lipidomics research found that Jianpi Lishi Formula has a regulatory effect on liver lipid composition.  CONCLUSION  Jianpi Lishi Formula has the effects of reducing body mass, regulating blood sugar, and protecting the liver. Lipidomics study indicates that the relief of NAFLD induced by Jianpi Lishi Formula may be related to the regulation of liver lipid composition.

     

    • FullText(HTML)
  • loading
    • References(24)
  • [1]
    REN TY, FAN JG. What are the clinical settings and outcomes of lean NAFLD?[J]. Nat Rev Gastroenterol Hepatol, 2021, 18(5): 289-290. doi: 10.1038/s41575-021-00433-5
    [2]
    中华医学会肝脏病学分会脂肪肝和酒精性肝病学组. 非酒精性脂肪性肝病诊断标准[J]. 中华肝脏病杂志, 2003, 11(2): 71.

    Fatty Liver and Alcoholic Liver Disease Study Group of Chinese Liver Disease Association. Diagnostic criteria of nonalcoholic fatty liver disease[J]. Chin J Hepatol, 2003, 11(2): 71.
    [3]
    张旭, 胡振斌, 徐昆, 等. 中医药防治非酒精性脂肪性肝病研究进展[J]. 河南中医, 2021, 41(9): 1427-1431.

    ZHANG X, HU ZB, XU K, et al. Research progress of prevention and treatment of nonalcoholic fatty liver disease with TCM[J]. Henan Tradit Chin Med, 2021, 41(9): 1427-1431.
    [4]
    谢博文. NASH肝细胞线粒体自噬机制及"脂肝方"的干预效应探讨[D]. 南宁: 广西中医药大学, 2018.

    XIE BW. Mechanism of mitochondrial autophagy in NASH hepatocytes and the intervention effect of "Zhiganfang"[D]. Nanning: Guangxi University of Chinese Medicine, 2018.
    [5]
    吴丽, 张峰, 郑仕中, 等. 中医药治疗非酒精性脂肪肝的研究进展[J]. 中成药, 2015, 37(5): 1072-1075. https://www.cnki.com.cn/Article/CJFDTOTAL-ZCYA201505032.htm

    WU L, ZHANG F, ZHENG SZ, et al. Research progress on treatment of nonalcoholic fatty liver with traditional Chinese medicine[J]. Chin Tradit Pat Med, 2015, 37(5): 1072-1075. https://www.cnki.com.cn/Article/CJFDTOTAL-ZCYA201505032.htm
    [6]
    叶青艳, 陈逸云, 陈建杰. 陈建杰从"肥人多痰湿"论治非酒精性脂肪性肝病经验[J]. 辽宁中医杂志, 2014, 41(1): 26-28. https://www.cnki.com.cn/Article/CJFDTOTAL-LNZY201401010.htm

    YE QY, CHEN YY, CHEN JJ. Experience of professor CHEN Jianjie's experience on using theory of obesity phlegm and dampness of TCM in treatment of nonalcoholic fatty liver disease[J]. Liaoning J Tradit Chin Med, 2014, 41(1): 26-28. https://www.cnki.com.cn/Article/CJFDTOTAL-LNZY201401010.htm
    [7]
    顾成娟, 王涵, 朴春丽. 生薏苡仁、茯苓、山药治疗虚胖经验: 仝小林三味小方撷萃[J]. 吉林中医药, 2020, 40(6): 712-714. https://www.cnki.com.cn/Article/CJFDTOTAL-ZYJL202006004.htm

    GU CJ, WANG H, PIAO CL. Experience in the treatment of puffiness with Coix seed, Poria and common yam rhizome—Three prescription by professor TONG Xiaolin[J]. Jilin J Chin Med, 2020, 40(6): 712-714. https://www.cnki.com.cn/Article/CJFDTOTAL-ZYJL202006004.htm
    [8]
    杨瑞, 钱文娟, 彭琳秀, 等. 基于UHPLC-Q-Exactive Orbitrap/MS的桔梗汤治疗小鼠急性肺损伤的磷脂组学研究[J]. 药学学报, 2019, 54(1): 144-150. https://www.cnki.com.cn/Article/CJFDTOTAL-YXXB201901023.htm

    YANG R, QIAN WJ, PENG LX, et al. Phospholipidomics study of Jiegeng Decotion for LPS-induced acute lung injury in mice based on UHPLC-Q-Exactive Orbitrap/MS[J]. China Ind Econ, 2019, 54(1): 144-150. https://www.cnki.com.cn/Article/CJFDTOTAL-YXXB201901023.htm
    [9]
    VANCE JE. Phospholipid synthesis and transport in mammalian cells[J]. Traffic, 2015, 16(1): 1-18. doi: 10.1111/tra.12230
    [10]
    崔鹤蓉, 王睿林, 郭文博, 等. 茯苓的化学成分、药理作用及临床应用研究进展[J]. 西北药学杂志, 2019, 34(5): 694-700. https://www.cnki.com.cn/Article/CJFDTOTAL-XBYZ201905030.htm

    CUI HR, WANG RL, GUO WB, et al. Research advances in chemical components, pharmacological activities and clinical application of Poria cocos[J]. Northwest Pharm J, 2019, 34(5): 694-700. https://www.cnki.com.cn/Article/CJFDTOTAL-XBYZ201905030.htm
    [11]
    李思博, 闫美怡, 刘阳. 降血脂中药功效分类及作用机制研究进展[J]. 辽宁中医药大学学报, 2021, 23(5): 166-169. https://www.cnki.com.cn/Article/CJFDTOTAL-LZXB202105037.htm

    LI SB, YAN MY, LIU Y. Research progress on classification and mechanism of efficacy of Chinese medicine for lowering blood lipid[J]. J Liaoning Univ Tradit Chin Med, 2021, 23(5): 166-169. https://www.cnki.com.cn/Article/CJFDTOTAL-LZXB202105037.htm
    [12]
    张晓航, 郝元兵, 张天奇. 中药山药的成分及药理学研究[J]. 中国食品, 2021(13): 118-119.

    ZHANG XH, HAO YB, ZHANG TQ. Study on the composition and pharmacology of Chinese medicine yam[J]. China Food, 2021(13): 118-119.
    [13]
    HU YF, HE WZ, HUANG YP, et al. Fatty acid synthase-suppressor screening identifies sorting nexin 8 as a therapeutic target for NAFLD[J]. Hepatology, 2021, 74(5): 2508-2525.
    [14]
    JANG H, LEE GY, SELBY CP, et al. SREBP1c-CRY1 signalling represses hepatic glucose production by promoting FOXO1 degradation during refeeding[J]. Nat Commun, 2016, 7: 12180.
    [15]
    GUO YW, ZHANG XY, ZHAO ZY, et al. NF-κB/HDAC1/SREBP1c pathway mediates the inflammation signal in progression of hepatic steatosis[J]. Acta Pharm Sin B, 2020, 10(5): 825-836.
    [16]
    HAN XL. Lipidomics for studying metabolism[J]. Nat Rev Endocrinol, 2016, 12(11): 668-679.
    [17]
    CHE L, CHI WN, QIAO Y, et al. Cholesterol biosynthesis supports the growth of hepatocarcinoma lesions depleted of fatty acid synthase in mice and humans[J]. Gut, 2020, 69(1): 177-186.
    [18]
    FRITSCHE KL. The science of fatty acids and inflammation[J]. Adv Nutr, 2015, 6(3): 293S-301S.
    [19]
    HIRSOVA P, IBRAHIM SH, KRISHNAN A, et al. Lipid-induced signaling causes release of inflammatory extracellular vesicles from hepatocytes[J]. Gastroenterology, 2016, 150(4): 956-967.
    [20]
    CUI F, ZHANG YL, WEI QM, et al. A novel medical treatment for lipid control in patients with unstable angina pectoris and statin-induced liver dysfunction[J]. Acta Cardiol Sin, 2015, 31(1): 66-71.
    [21]
    张乾, 董雪莲. 温阳化浊方联合多烯磷脂酰胆碱治疗非酒精性脂肪肝的临床观察[J]. 中国民间疗法, 2021, 29(3): 82-85.

    ZHANG Q, DONG XL. Clinical observation of Wenyang Huazhuo Decoction combined with polyene phosphatidylcholine in treating non-alcoholic fatty liver disease[J]. China's Naturopath, 2021, 29(3): 82-85.
    [22]
    LI ZH, WANG FX, LIANG BY, et al. Methionine metabolism in chronic liver diseases: An update on molecular mechanism and therapeutic implication[J]. Signal Transduct Target Ther, 2020, 5(1): 280.
    [23]
    FONDEVILA MF, FERNANDEZ U, GONZALEZ-RELLAN MJ, et al. The L-α-lysophosphatidylinositol/G protein-coupled receptor 55 system induces the development of nonalcoholic steatosis and steatohepatitis[J]. Hepatology, 2021, 73(2): 606-624.
    [24]
    SUN XL, SEIDMAN JS, ZHAO P, et al. Neutralization of oxidized phospholipids ameliorates non-alcoholic steatohepatitis[J]. Cell Metab, 2020, 31(1): 189-206.
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Figures(7)  / Tables(5)

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (231) PDF downloads(34) Cited by()
    Proportional views
    Related

    Copyright © Journal of Nanjing University of traditional Chinese Medicine

    Sponsored by：Nanjing University of traditional Chinese MedicineAddress：No.138 xianlin Avenue, Qixia District, Nanjing cityChina Pos：210023

    Tel：025-85811935Email：xb@njucm.edu.cn

    Supported by: Beijing Renhe Information Technology Co., Ltd.    

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return